Suppr超能文献

一个用于评估持续使用Mobius3D的行动水平和耐受性的临床数据库。

A clinical database to assess action levels and tolerances for the ongoing use of Mobius3D.

作者信息

Jolly David, Dunn Leon, Kenny John

机构信息

Epworth Radiation Oncology Research Centre, Epworth HealthCare, Melbourne, VIC, Australia.

出版信息

J Appl Clin Med Phys. 2017 Jan;18(1):59-65. doi: 10.1002/acm2.12009. Epub 2016 Nov 30.

Abstract

In radiation therapy, calculation of dose within the patient contains inherent uncertainties, inaccuracies, limitations, and the potential for random error. Thus, point dose-independent verification of such calculations is a well-established process, with published data to support the setting of both action levels and tolerances. Mobius3D takes this process one step further with a full independent calculation of patient dose and comparisons of clinical parameters such as mean target dose and voxel-by-voxel gamma analysis. There is currently no published data to directly inform tolerance levels for such parameters, and therefore this work presents a database of 1000 Mobius3D results to fill this gap. The data are tested for normality using a normal probability plot and found to fit this distribution for three sub groups of data; Eclipse, iPlan and the treatment site Lung. The mean (μ) and standard deviation (σ) of these sub groups is used to set action levels and tolerances at μ ± 2σ and μ ± 3σ, respectively. A global (3%, 3 mm) gamma tolerance is set at 88.5%. The mean target dose tolerance for Eclipse data is the narrowest at ± 3%, whilst iPlan and Lung have a range of -5.0 to 2.2% and -1.8 to 5.0%, respectively. With these limits in place, future results failing the action level or tolerance will fall within the worst 5% and 1% of historical results and an informed decision can be made regarding remedial action prior to treatment.

摘要

在放射治疗中,患者体内剂量的计算存在固有的不确定性、不准确性、局限性以及随机误差的可能性。因此,对这类计算进行与点剂量无关的验证是一个成熟的过程,有已发表的数据支持行动水平和公差的设定。Mobius3D将这一过程更进一步,对患者剂量进行完全独立的计算,并对平均靶区剂量和逐体素伽马分析等临床参数进行比较。目前尚无已发表的数据直接告知此类参数的公差水平,因此这项工作提供了一个包含1000个Mobius3D结果的数据库来填补这一空白。使用正态概率图对数据进行正态性检验,发现三组数据(Eclipse、iPlan和治疗部位肺)均符合该分布。这些子组的均值(μ)和标准差(σ)分别用于设定行动水平和公差,分别为μ±2σ和μ±3σ。全局(3%,3毫米)伽马公差设定为88.5%。Eclipse数据的平均靶区剂量公差最窄,为±3%,而iPlan和肺的范围分别为-5.0%至2.2%和-1.8%至5.0%。有了这些限制,未来未达到行动水平或公差的结果将落在历史结果最差的5%和1%范围内,从而可以在治疗前就补救措施做出明智的决定。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afaf/5689886/8a4b9594e059/ACM2-18-059-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验